Hyundai Bioscience Co., Ltd.

Research Hyundai Bioscience Co., Ltd. (048410.KQ) on Bullrun: market cap KRW 632.10B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is KRW 632.10B.

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18KRW 632.10Bn/an/an/a

Dividend history

About Hyundai Bioscience Co., Ltd.

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.

Related stock research

South Korea stocks South Korea Healthcare stocks A-Z stock index

Other Healthcare stocks

ORIENT BIO Inc. (002630.KS) GC Corp. (005250.KS) Pharmicell Co., Ltd. (005690.KS) Kanaph Therapeutics Inc. (0082N0.KQ) Samik Pharmaceutical Company LTD. (014950.KQ) HLB Co., Ltd. (028300) Mgen Solutions Co., Ltd. (032790.KQ) Daesung Microbiological Labs. Co., Ltd. (036480.KQ) Seoulin Bioscience Co.,Ltd. (038070.KQ) iNtRON Biotechnology, Inc. (048530.KQ) Synergy Innovation Co., Ltd. (048870.KQ) CTCBIO Inc. (060590.KQ)

Frequently asked questions

What is Hyundai Bioscience Co., Ltd.'s market cap?

Hyundai Bioscience Co., Ltd.'s market capitalization is KRW 632.10B.

What does Hyundai Bioscience Co., Ltd. do?

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.